Director J. Erik Fyrwald filed a Form 4 with the SEC on November 17, 2026, disclosing two acquisitions of Eli Lilly common stock on November 16, 2026, under the company's Directors' Deferral Plan.

Key Highlights

  • Reporting person: J. Erik Fyrwald, Director at Eli Lilly & Co (NYSE:LLY)
  • First acquisition: 6.9266 shares acquired at $1,431.67 per share on November 16, 2026
  • Second acquisition: 167.6364 shares acquired at $1,431.67 per share on November 16, 2026
  • Post-transaction holdings: 75,718.6889 shares of common stock held directly following both transactions
  • Deferral election: The 6.9266 shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan, to be settled in common stock following separation from service
  • Filing signed: By Jonathan Groff for J. Erik Fyrwald, pursuant to authorization on file, dated November 17, 2026

Fyrwald's November 16 Share Acquisitions Under Lilly Directors' Deferral Plan

According to the filing, Director J. Erik Fyrwald reported two separate acquisitions of Eli Lilly & Co common stock on November 16, 2026, both coded as acquisitions (Code A). The first transaction involved 6.9266 shares at a price of $1,431.67 per share. Per footnote 1, these shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and "will be settled in shares of common stock following the reporting person's separation from service."

The second transaction on the same date involved 167.6364 shares, also acquired at $1,431.67 per share, and reported as a direct holding. Following both transactions, Fyrwald's total direct beneficial ownership of common stock stood at 75,718.6889 shares, as disclosed in the filing. Prior to the second transaction, his holdings were reported at 75,551.0525 shares.

The Form 4 was filed on November 17, 2026, and signed by Jonathan Groff on behalf of J. Erik Fyrwald pursuant to an authorization on file. No derivative securities were reported in Table II of the filing. No amendment to a prior filing was indicated.

What Was Disclosed

Director J. Erik Fyrwald disclosed two acquisitions of Eli Lilly common stock on November 16, 2026, totaling 174.5630 shares at $1,431.67 each, with one tranche deferred under the Lilly Directors' Deferral Plan, bringing his direct holdings to 75,718.6889 shares.